Future of flu vaccines. Expediting clinical trials in a pandemic.

Future of flu vaccines. Expediting clinical trials in a pandemic.

Čájet eará veršuvnnaid (1)

Bibliográfalaš dieđut
Váldodahkkit:	Pollard, A, Reiner, A, John, T, Sheasby, E, Snape, M, Faust, S, Collinson, A, Finn, A, Heath, P, Miller, E
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	2009

Geahča maid

Future of flu vaccines. Expediting clinical trials in a pandemic.
Dahkki: Pollard, A, et al.
Almmustuhtton: (2009)

Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
Dahkki: Walker, W, et al.
Almmustuhtton: (2011)

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
Dahkki: Waddington, C, et al.
Almmustuhtton: (2010)

Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
Dahkki: Waddington, C, et al.
Almmustuhtton: (2010)

Pandemic vaccine trials: expedite, but don’t rush
Dahkki: Angus Dawson
Almmustuhtton: (2020-07-01)

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
Dahkki: Waddington, C, et al.
Almmustuhtton: (2010)

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
Dahkki: Andrews, N, et al.
Almmustuhtton: (2011)

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
Dahkki: Andrews, N, et al.
Almmustuhtton: (2011)

Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
Dahkki: Andrews, N, et al.
Almmustuhtton: (2011)

Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03B/oil-in-water emulsion-adjuvanted (AS03B) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age
Dahkki: CS Waddington, et al.
Almmustuhtton: (2010-10-01)

The case for mandatory flu vaccination of children.
Dahkki: Bambery, B, et al.
Almmustuhtton: (2013)

Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy
Dahkki: Pace, D, et al.
Almmustuhtton: (2016)

100 Years after the Spanish Flu Pandemic. The Evolution of the Influenza Virus and the Development of the Flu Vaccine
Dahkki: N. I. Briko
Almmustuhtton: (2018-09-01)

Effectiveness of the flu vaccine to prevent severe flu
Dahkki: Francisco Miguel Escandell-Rico, et al.
Almmustuhtton: (2023-01-01)

Cell culture-derived flu vaccine: Present and future
Dahkki: Alberto Pérez Rubio, et al.
Almmustuhtton: (2018-08-01)

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
Dahkki: Hoschler, K, et al.
Almmustuhtton: (2014)

Results of Clinical Trials of the First Russian 4-valent Flu Vaccine
Dahkki: D. A. Lioznov
Almmustuhtton: (2018-09-01)

Pneumococcal serotype-specific antibodies persist through early childhood after infant immunization: follow-up from a randomized controlled trial
Dahkki: Trück, J, et al.
Almmustuhtton: (2014)

The 1918 flu pandemic and its aftermath
Dahkki: Norman A. Johnson
Almmustuhtton: (2018-04-01)

Flu vaccination in the Philippines: challenges and interventions
Dahkki: Dalmacito A. Cordero
Almmustuhtton: (2023-11-01)

Determinants of adults' intention to vaccinate against pandemic swine flu
Dahkki: Goodwin Robin, et al.
Almmustuhtton: (2011-01-01)

HIV false positive results and Flu vaccination
Dahkki: A Moradi, et al.
Almmustuhtton: (2007-10-01)

NEURAMINIDASE INHIBITORS — NEW OPPORTUNITIES IN THE FLU TREATMENT IN RECENT YEARS, WHEN SOMEONE SAYS FLU, DOCTORS RECALL SUCH A THING, AS «THE VACCINATION AGAINST THE FLU».
Dahkki: M.D. Bakradze, et al.
Almmustuhtton: (2007-04-01)

NEURAMINIDASE INHIBITORS — NEW OPPORTUNITIES IN THE FLU TREATMENT IN RECENT YEARS, WHEN SOMEONE SAYS FLU, DOCTORS RECALL SUCH A THING, AS «THE VACCINATION AGAINST THE FLU».
Dahkki: M.D. Bakradze, et al.
Almmustuhtton: (2007-04-01)

Communicating to increase public uptake of pandemic flu vaccination in the UK: Which messages work?
Dahkki: Mowbray, F, et al.
Almmustuhtton: (2016)

Pandemic flu: communicating the risks
Almmustuhtton: (2006-01-01)

Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.
Dahkki: Pace, D, et al.
Almmustuhtton: (2015)

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
Dahkki: de Whalley, P, et al.
Almmustuhtton: (2011)

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
Dahkki: de Whalley, P, et al.
Almmustuhtton: (2011)

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
Dahkki: de Whalley, P, et al.
Almmustuhtton: (2011)

Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial.
Dahkki: Snape, MD, et al.
Almmustuhtton: (2010)

VACCINATION AGAINST PNEUMOCOCCAL INFECTION DURING THE PREPARATION FOR A PROBABLE FLU PANDEMIC
Dahkki: M.V. Fedoseenko, et al.
Almmustuhtton: (2008-09-01)

VACCINATION AGAINST PNEUMOCOCCAL INFECTION DURING THE PREPARATION FOR A PROBABLE FLU PANDEMIC
Dahkki: M.V. Fedoseenko, et al.
Almmustuhtton: (2008-09-01)

A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children
Dahkki: P de Whalley, et al.
Almmustuhtton: (2011-12-01)

Meningococcal polysaccharide-protein conjugate vaccines.
Dahkki: Snape, MD, et al.
Almmustuhtton: (2005)

Improving preparedness for the next flu pandemic
Dahkki: Horby, P
Almmustuhtton: (2018)

Canadian survey on pandemic flu preparations
Dahkki: Tracy CS, et al.
Almmustuhtton: (2010-03-01)

Mitigation approaches to combat the flu pandemic
Dahkki: Raman Chawla, et al.
Almmustuhtton: (2009-01-01)

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
Dahkki: Walker, W, et al.
Almmustuhtton: (2012)

Online survey on barriers and drivers to flu vaccination among staff at a German university hospital during the Covid-19 pandemic 2022 (flu-vaccination motive study)
Dahkki: Schmidt-Bandelin, Annika, et al.
Almmustuhtton: (2024-12-01)